Burning Rock Biotech Ltd. ADR (BNR) News

Burning Rock Biotech Ltd. ADR (BNR): $7.55

0.02 (-0.26%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Filter BNR News Items

BNR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BNR News Highlights

  • For BNR, its 30 day story count is now at 4.
  • Over the past 20 days, the trend for BNR's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • ROCK, NGS and ACT are the most mentioned tickers in articles about BNR.

Latest BNR News From Around the Web

Below are the latest news stories about BURNING ROCK BIOTECH LTD that investors may wish to consider to help them evaluate BNR as an investment opportunity.

Burning Rock Announces Results of 2023 Annual General Meeting

GUANGZHOU, China, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2023 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: To ratify the appointment of Ernst & You

Yahoo | December 20, 2023

Burning Rock Biotech Limited (NASDAQ:BNR) Q3 2023 Earnings Call Transcript

Burning Rock Biotech Limited (NASDAQ:BNR) Q3 2023 Earnings Call Transcript November 30, 2023 Operator: Before we begin, I would like to remind you that this conference call contains forward-looking statements within the meaning of the Section 21E of the Securities Exchange Act of 1934 as amended and as defined in the U.S. Private Securities Litigation […]

Yahoo | December 1, 2023

Q3 2023 Burning Rock Biotech Ltd Earnings Call

Q3 2023 Burning Rock Biotech Ltd Earnings Call

Yahoo | December 1, 2023

Burning Rock Reports Third Quarter 2023 Financial Results

GUANGZHOU, China, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2023. Recent Business Updates Therapy Selection and Minimal Residual Disease (MRD) Personalized Minimal Residual Disease (MRD) product, brPROPHETTM supports advance

Yahoo | November 30, 2023

Burning Rock Announces 2023 Annual General Meeting to be Held on December 20, 2023

GUANGZHOU, China, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting (“AGM”) on December 20, 2023 at 10:00 a.m. (local time) at the Company’s Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District,

Yahoo | November 22, 2023

Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023

GUANGZHOU, China, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the third quarter of 2023 before the U.S. market opens on November 30, 2023. Following the release, company management will host a conference call at 7:00 a.m. E

Yahoo | November 21, 2023

Burning Rock Biotech Limited's (NASDAQ:BNR) largest shareholders are individual investors with 29% ownership, institutions own 26%

Key Insights The considerable ownership by individual investors in Burning Rock Biotech indicates that they...

Yahoo | October 31, 2023

Burning Rock and Boehringer Ingelheim Achieved a Master Service Agreement in Oncology Companion Diagnostics

GUANGZHOU, China, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that the Company and Boehringer Ingelheim officially have signed the Master Service Agreement (MSA) in the field of oncology companion diagnostics. This agreement aims to provide Chinese patients with safer, more efficient, and precise treatment options and diagnostic methods, thereby promoting innovation and development in cancer tre

Yahoo | October 30, 2023

Burning Rock Received Breakthrough Device Designation from China’s NMPA for its Multi-Cancer Early Detection Test

GUANGZHOU, China, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that followed an earlier Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for its OverC™ Multi-Cancer Detection Blood Test (MCDBT) in January 2023, its OverC™ MCDBT has been granted Breakthrough Device Designation by the China National Medical Products Administration(NMPA), which represents the only

Yahoo | October 15, 2023

Burning Rock's minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell

GUANGZHOU, China, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is delighted to announce that our personalized Minimal Residual Disease (MRD) product, CanCatch® (PROPHETTM panel), was enrolled in a prospective observational study (MEDAL, MEthylation based Dynamic Analysis for Lung cancer, NCT03634826). The MEDAL is a 5-year study that aimed to investigate the clinical utility of MRD in patients with non-small cell lung

Yahoo | September 8, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!